Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Vertex Pharmaceuticals Inc
Recent news which mentions Vertex Pharmaceuticals Inc
Trump's pharmaceutical tariffs could affect some drugmakers more than others
July 29, 2025
Tags
Companies
AbbVie Inc
Novartis AG
From
CNBC.com News
Healthy Returns: Medicaid cuts in Trump’s megabill may affect some drugmakers more than others
July 08, 2025
Tags
Gilead Sciences Inc
Healthy Returns
Bristol/Myers Squibb Co
From
CNBC.com News
Cramer's week ahead: Earnings from Disney, Palantir and Uber
May 02, 2025
Tags
Markets
Investing
Novo Nordisk A/S
From
CNBC.com News
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
April 01, 2025
Tags
Vertex Pharmaceuticals Inc
Breaking News: Markets
Health & Science
From
CNBC.com News
Jim Cramer says 'the market may be far healthier than we think.' Here's why
March 27, 2025
Tags
Chevron Corp
Investing
Markets
From
CNBC.com News
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
February 21, 2025
Tags
Vertex Pharmaceuticals Inc
bluebird bio Inc
Business News
From
CNBC.com News
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
February 18, 2025
Tags
Business News
bluebird bio Inc
Vertex Pharmaceuticals Inc
From
CNBC.com News
FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades
January 30, 2025
Tags
Business
Companies
Vertex Pharmaceuticals Inc
From
CNBC.com News
Cramer's Lightning Round: 'I would be a seller of QuantumScape'
January 08, 2025
Tags
Pfizer Inc
Investment strategy
Serve Robotics Inc
From
CNBC.com News
Cramer's Lightning Round: Vertex Pharmaceuticals is a buy
October 30, 2024
Tags
stocks
Business
Vertex Pharmaceuticals Inc
From
CNBC.com News
Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it matters
October 01, 2024
Tags
Biotech and Pharmaceuticals
Agios Pharmaceuticals Inc
Hacking
From
CNBC.com News
Cramer's Lightning Round: Builders FirstSource 'can go higher'
August 28, 2024
Tags
Vertex Pharmaceuticals Inc
Business News
Business
From
CNBC.com News
Cramer's Lighting Round: Vertex Pharmaceuticals is 'terrific'
April 08, 2024
Tags
Market Outlook
Ford Motor Co
Emerson Electric Co
From
CNBC.com News
New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle
February 23, 2024
Tags
Business News
Social issues
bluebird bio Inc
From
CNBC.com News
Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain
January 30, 2024
Tags
CRISPR Therapeutics AG
US: News
Biotech and Pharmaceuticals
From
CNBC.com News
Vertex shares pop after non-opioid painkiller posts positive mid-stage trial results
December 13, 2023
Tags
Vertex
Biotech and Pharmaceuticals
Breaking news
From
CNBC.com News
U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease
December 08, 2023
Tags
Business News
Vertex Pharmaceuticals Inc
Business
From
CNBC.com News
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients
December 07, 2023
Tags
Health & Science
Government Agencies
Biotech and Pharmaceuticals
From
CNBC.com News
Here are 16 stocks Jim Cramer is watching, including Microsoft, Chevron, Southwest
October 30, 2023
Tags
Abbvie Inc
Markets
Investing
From
CNBC.com News
20 stocks I'm watching in the market, including Emerson, DoorDash, Royal Caribbean
October 09, 2023
Tags
Vertex Pharmaceuticals Inc
Ingersoll Rand Inc
3M Co
From
CNBC.com News
Cramer says Vertex has a drug that may address the 'largest market opportunity in the world'
October 09, 2023
Tags
Vertex Pharmaceuticals Inc
CNBC Investing Club: Analysis
Investing
From
CNBC.com News
Cramer's Lightning Round: Vertex is 'excellent'
October 05, 2023
Tags
S&P 500
Stock markets
Under Armour Inc
From
CNBC.com News
Stocks making the biggest moves after hours: Arista Networks, MGM Resorts, Stryker and more
May 01, 2023
Tags
MGM Resorts International
Stryker Corp
Stock markets
From
CNBC.com News
Stocks making the biggest moves midday: Walgreens, Coinbase, Duolingo, Ralph Lauren and more
November 11, 2022
Tags
UBS Group AG
Amazon/com Inc
Vertex Pharmaceuticals Inc
From
CNBC.com News
Cramer's lightning round: Stay with Vertex Pharmaceuticals
October 27, 2022
Tags
Mad Money
Markets
Investing
From
CNBC.com News
Stocks making the biggest moves after hours: Amazon, Apple, Pinterest, Intel and more
October 27, 2022
Tags
Finance
Gilead Sciences Inc
Market Insider
From
CNBC.com News
Jim Cramer says investors should eye these three tech names in the Nasdaq 100
July 05, 2022
Tags
Meta Platforms Inc
Investment strategy
Activision Blizzard Inc
From
CNBC.com News
Cramer's lightning round: I'm sticking with Marvell Technology
June 22, 2022
Tags
Market Outlook
Devon Energy Corp
EOG Resources Inc
From
CNBC.com News
Stocks making the biggest moves midday: Global Payments, Moderna, Activision Blizzard and more
May 02, 2022
Tags
Breaking News: Markets
stocks
Activision Blizzard Inc
From
CNBC.com News
Some of the first quarter’s biggest losers could be the biggest steals, Jim Cramer says
April 04, 2022
Tags
AstraZeneca PLC
Salesforce Inc
Nike Inc
From
CNBC.com News
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.